20 recruiting, 4 completed, 4 unknown, 3 not yet recruiting. 16 Phase 2, 9 Phase 1, 5 Phase 3, 3 Not applicable, 1 Early Phase 1.
Follow olverembatinib: new trials by email Literature Review of olverembatinib trials Research Report on olverembatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL olverembatinib, Venetoclax, Inotuzumab Ozogamicin (IO) - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 22 | 2026-10-12 | 2026-09-25 |
| ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL Olverembatinib, Gecacitinib, Venetoclax - Ph-Like, Acute Lymphoblastic Leukemia | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 92 | 2026-05-30 | 2026-05-13 |
| Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL Olverembatinib, Venetoclax, Blinatumomab - Ph+ ALL | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 110 | 2026-04-10 | 2026-07-23 |
| Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase Olverembatinib 20mg - Chronic Myeloid Leukemia | Enrolling by invitation | Qian Jiang | 100 | 2025-12-16 | 2026-02-03 | |
| Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment Olverembatinib 20mg - Pharmacokinetic, Olverembatinib | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 48 | 2025-11-11 | 2025-12-23 |
| Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib olverembatinib - Chronic Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2025-10-13 | 2026-10-01 |
| Newly-diagnosed Pediatric Ph-positive B-ALL Protocol olverembatinib - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic | Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 150 | 2025-03-28 | 2025-09-03 |
| Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML Olverembatinib, Venetoclax, Azacitidine - CML,Blast Phase | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 29 | 2025-01-26 | 2025-05-30 |
| Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL Venetoclax, Olverembatinib, Predinisone - Precursor B-Cell Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 36 | 2024-12-01 | 2024-12-31 |
| A Study of Olverembatinib in SDH-deficient GIST. Olverembatinib - GIST | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 40 | 2024-11-11 | 2026-07-23 |
| A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia Decitabine, Listaftoclax, Olverembatinib - Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-08-06 | 2026-09-25 |
| The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP Ponatinib, Azacitidine, Venetoclax - Chronic Myeloid Leukemia | Recruiting | Peking University People's Hospital | 30 | 2024-07-01 | 2025-06-03 | |
| Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL CAR-T cells, Venetoclax, Olverembatinib - Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 82 | 2024-06-04 | 2026-03-02 |
| Study of Olverembatinib (HQP1351) in Patients With CML-CP olverembatinib, Bosutinib - Chronic Myeloid Leukemia, CML | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 333 | 2024-02-05 | 2026-09-15 |
| A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL Prednisone, Olverembatinib, Blinatumomab, Chidamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 67 | 2024-02-01 | 2024-01-24 |
| Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. ThisCART19A, Fludarabine, Cyclophosphamide - Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 20 | 2024-01-01 | 2026-06-17 |
| Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia Olverembatinib plus venetoclax and dexamethasone - Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Xijing Hospital | 30 | 2023-11-01 | 2023-10-13 |
| A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) Olverembatinib, Investigator's choice of TKI - Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 350 | 2023-08-31 | 2026-04-30 |
| A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL Olverembatinib - Philadelphia-Positive ALL | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 22 | 2023-07-01 | 2023-07-05 |
Showing 20 of 34. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Leukemia, Myeloid, Chronic-Phase (5) · Gastrointestinal Stromal Tumors (1) · Leukemia (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Myeloproliferative Disorders (1) · Philadelphia Chromosome (1) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1)
Ascentage Pharma Group Inc. (12) · Institute of Hematology & Blood Diseases Hospital, China (8) · M.D. Anderson Cancer Center (3) · The First Affiliated Hospital of Soochow University (3) · Chen Suning (1) · First Affiliated Hospital of Zhejiang University (1) · Nanfang Hospital, Southern Medical University (1) · Peking University People's Hospital (1) · Qian Jiang (1) · Shenzhen Second People's Hospital (1) · Xijing Hospital (1) · xuna (1)
China (29) · United States (5) · Australia (2) · France (2) · Italy (2) · Singapore (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Czechia (1) · Germany (1) · Hong Kong (1)
Xiaojun Huang, Professor (3) · Elias Jabbour, M.D. (2) · Jianxiang Wang, Dr (2) · Qian Jiang, Professor (2) · Xiaofan Zhu, MD (2) · Congcong Wang (1) · Elias J Jabbour, MD (1) · Fadi Haddad, MD (1) · Feng Shao, Doctor (1) · Hongsheng Zhou, M.D., Ph.D (1) · Jiali Yao (1) · Jie Jin (1) · Jie Jin, M.D. (1) · Liyan Miao, M.D.,Ph.D. (1) · Nicholas Short, MD (1)